ReviewJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy2016
Fosfomycin: Resurgence of an old companion.
Review in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03287089 (Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery), which is not on this map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery (NAUTICA): A Randomized Controlled Trial
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.
- A Systematic Review of Single-Dose Aminoglycoside Therapy for Urinary Tract Infection: Is It Time To Resurrect an Old Strategy?Antimicrobial agents and chemotherapy · 2019Pooled it
- Fosfomycin Resistance in Escherichia coli: Mechanisms, Trends, and Clinical Challenges.Cureus · 2026Review
- Coexistence of blaBMC microbiology · 2026Article
- Deoxynivalenol-induced apoptosis and IL-1β modulation by fosfomycin in porcine immune and human intestinal epithelial cells.Veterinary research communications · 2026Article
- Fosfomycin resistance determinants in Escherichia coli isolates of human and animal origin from Iran.Molecular biology reports · 2025Article
- Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis.Antimicrobial agents and chemotherapy · 2025Article
- Management practices and mortality predictors among Klebsiella pneumoniae infections across Lebanese hospitals: a multicenter retrospective study.BMC infectious diseases · 2025Observational
- Metabolomics reveals the mechanisms of action of fosfomycin and azithromycin combination in the treatment ofFrontiers in cellular and infection microbiology · 2025Article
- Investigation of the Effects of Fosfomycin in Kidney Damage Caused by CLP-Induced Sepsis.Life (Basel, Switzerland) · 2024Article
- Effect of fosfomycin-induced hypernatremia on patients' hospital stay length and survival.Irish journal of medical science · 2024Article
- Raising the alarm: fosfomycin resistance associated with non-susceptible inner colonies imparts no fitness cost to the primary bacterial uropathogen.Antimicrobial agents and chemotherapy · 2024Article
- Molecular epidemiology of extended-spectrum beta-lactamase-producing-Frontiers in microbiology · 2024Article
- Systematic analysis of drug combinations against Gram-positive bacteria.Nature microbiology · 2023Article
- [UhpTNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Incidence and Genomic Background of Antibiotic Resistance in Food-Borne and Clinical Isolates ofAntibiotics (Basel, Switzerland) · 2023Article
- Efficacy of Fosfomycin against Planktonic and Biofilm-Associated MDR UropathogenicTropical medicine and infectious disease · 2022Article
- Factorial design and post-antibiotic sub-MIC effects of linezolid combined with fosfomycin against vancomycin-resistant enterococci.Annals of translational medicine · 2022Article
- Antibiotic Use and Resistance Knowledge Assessment of Personnel on Chicken Farms with High Levels of Antimicrobial Resistance: A Cross-Sectional Survey in Ica, Peru.Antibiotics (Basel, Switzerland) · 2022Article
- Role of peptidoglycan recycling enzymes AmpD and AnmK inFrontiers in cellular and infection microbiology · 2022Article
- Understanding tolerance to cell wall-active antibiotics.Annals of the New York Academy of Sciences · 2021Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Fosfomycin was discovered over four decades ago, yet has drawn renewed interest as an agent active against a range of multidrug-resistant (MDR) and extensively drug-resistant (XDR) pathogens. Its unique mechanism of action and broad spectrum of activity makes it a promising candidate in the treatment of various MDR/XDR infections. There has been a surge of in vitro data on its activity against MDR/XDR organisms, both when used as a single agent and in combination with other agents. In the United States, fosfomycin is only approved in an oral formulation for the treatment of acute uncomplicated urinary tract infections (UTIs), whereas in some countries both oral and intravenous formulations are available for various indications. Fosfomycin has minimal interactions with other medications and has a relatively favorable safety profile, with diarrhea being the most common adverse reaction. Fosfomycin has low protein binding and is excreted primarily unchanged in the urine. The clinical outcomes of patients treated with fosfomycin are favorable for uncomplicated UTIs, but data are limited for use in other conditions. Fosfomycin maintains activity against most Enterobacteriaceae including Escherichia coli, but plasmid-mediated resistance due to inactivation have appeared in recent years, which has the potential to compromise its use in the future. In this review, we summarize the current knowledge of this resurgent agent and its role in our antimicrobial armamentarium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.